This post was originally published on this site

BIOLASE, Inc. (NASDAQ:BIOL) shares gapped up prior to trading on Monday . The stock had previously closed at $0.53, but opened at $0.58. BIOLASE shares last traded at $0.56, with a volume of 44,299 shares traded.

Several research analysts recently weighed in on the stock. Zacks Investment Research cut shares of BIOLASE from a “buy” rating to a “sell” rating in a research report on Wednesday, October 14th. Maxim Group assumed coverage on shares of BIOLASE in a research report on Wednesday, October 14th. They issued a “buy” rating and a $1.00 price objective for the company.

The firm’s 50-day simple moving average is $0.34 and its 200 day simple moving average is $0.35. The company has a market cap of $50.36 million, a P/E ratio of -0.81 and a beta of 1.98. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.09 and a current ratio of 1.68.

BIOLASE (NASDAQ:BIOL) last issued its earnings results on Tuesday, November 17th. The medical technology company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.16). BIOLASE had a negative net margin of 58.34% and a negative return on equity of 541.14%. The business had revenue of $6.54 million for the quarter. As a group, research analysts forecast that BIOLASE, Inc. will post -0.25 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the company. Jane Street Group LLC acquired a new position in shares of BIOLASE during the 2nd quarter worth about $50,000. Virtu Financial LLC boosted its stake in shares of BIOLASE by 1,908.5% during the 3rd quarter. Virtu Financial LLC now owns 269,185 shares of the medical technology company’s stock worth $74,000 after buying an additional 255,783 shares during the last quarter. Finally, Perkins Capital Management Inc. acquired a new position in shares of BIOLASE during the 3rd quarter worth about $306,000. 5.52% of the stock is owned by institutional investors.

About BIOLASE (NASDAQ:BIOL)

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications.

Featured Article: What is the Shanghai Stock Exchange Composite Index?

Receive News & Ratings for BIOLASE Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BIOLASE and related companies with MarketBeat.com’s FREE daily email newsletter.